N-(6-chlorobenzothiazol-2-yl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)acetamide | 1171547-71-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: N-(6-chlorobenzothiazol-2-yl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)acetamide
• 英文别名: N-(6-chloro-1,3-benzothiazol-2-yl)-2-(3,5-dimethylpyrazol-1-yl)acetamide
• CAS: 1171547-71-9
• 化学式: C₁₄H₁₃ClN₄OS
• 分子量: 320.802
• InChiKey: ACJARJBZFKJTJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  88
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氨基-6-氯苯并噻唑 在 一水合肼 、 溶剂黄146 、 三乙胺 作用下， 以 四氯化碳 、 乙醇 为溶剂， 反应 10.0h， 生成 N-(6-chlorobenzothiazol-2-yl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)acetamide
  参考文献：
  名称：

  Synthesis and in vitro antitumor activity of new series of benzothiazole and pyrimido[2,1-b]benzothiazole derivatives

  摘要：

  New series of benzothiazole and pyrimido[2,1-b]benzothiazole derivatives were synthesized and characterized by analytical and spectrometrical methods (IR, HRMS, H-1 and C-13 NMR). Nineteen of the synthesized compounds were selected by the National Cancer Institute (NCI), USA, to be screened for their antitumor activity at a single dose (10 mu M) against a panel of 60 cancer cell lines. The most active compounds, 4, 6, 10, 14, 17 and 20 were selected for further evaluation at five dose level screening. Compounds 17 (GI(50) = 0.44 mu M, TGI = 1.2 mu M and LC50 MG-MID = 6.6 mu M) and 4 (GI(50) = 0.77 mu M, TGI = 2.08 mu M and LC50 MG-MID = 11.74 mu M) were proved to be the most active members in this study. 3D and 2D pharmacophoric maps for the structural features of both compounds were studied. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.07.097

文献信息

• Synthesis and in vitro antitumor activity of new series of benzothiazole and pyrimido[2,1-b]benzothiazole derivatives
  作者：Moustafa T. Gabr、Nadia S. El-Gohary、Eman R. El-Bendary、Mohamed M. El-Kerdawy

  DOI：10.1016/j.ejmech.2014.07.097

  日期：2014.10

  New series of benzothiazole and pyrimido[2,1-b]benzothiazole derivatives were synthesized and characterized by analytical and spectrometrical methods (IR, HRMS, H-1 and C-13 NMR). Nineteen of the synthesized compounds were selected by the National Cancer Institute (NCI), USA, to be screened for their antitumor activity at a single dose (10 mu M) against a panel of 60 cancer cell lines. The most active compounds, 4, 6, 10, 14, 17 and 20 were selected for further evaluation at five dose level screening. Compounds 17 (GI(50) = 0.44 mu M, TGI = 1.2 mu M and LC50 MG-MID = 6.6 mu M) and 4 (GI(50) = 0.77 mu M, TGI = 2.08 mu M and LC50 MG-MID = 11.74 mu M) were proved to be the most active members in this study. 3D and 2D pharmacophoric maps for the structural features of both compounds were studied. (C) 2014 Elsevier Masson SAS. All rights reserved.